COCP — Cocrystal Pharma Balance Sheet
0.000.00%
- $14.47m
- $6.74m
- 12
- 23
- 60
- 21
Annual balance sheet for Cocrystal Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 33 | 58.7 | 37.1 | 26.4 | 9.86 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.556 | 0 | 0.716 | 0.89 | 1.22 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 34 | 59.3 | 40.2 | 29.1 | 11.6 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.09 | 0.931 | 0.616 | 2.12 | 1.85 |
| Net Goodwill | |||||
| Long Term Investments | |||||
| Total Assets | 54.2 | 79.4 | 40.8 | 31.3 | 13.5 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.36 | 1.54 | 1.22 | 3.26 | 2.43 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.74 | 1.84 | 1.27 | 4.88 | 3.93 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 52.5 | 77.5 | 39.6 | 26.4 | 9.52 |
| Total Liabilities & Shareholders' Equity | 54.2 | 79.4 | 40.8 | 31.3 | 13.5 |
| Total Common Shares Outstanding |